DelveInsight’s ‘Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Progressive Fibrosing Interstitial Lung Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive Fibrosing Interstitial Lung Disease market size from 2019 to 2032. The Report also covers current Progressive Fibrosing Interstitial Lung Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Progressive Fibrosing Interstitial Lung Disease Report:
- The 7MM showed 341,936 diagnosed prevalent cases of Idiopathic Interstitial Pneumonia (IIPs). Furthermore, Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs cases were 211,244, 21,522, 244,607, and 75,287, respectively.
- These types contribute to the Progressive form of Interstitial Lung Disease through applied progression rate in each sub-types of these classes.
- The United States showed the most diagnosed prevalent cases of PF-ILD in the 7MM countries. In 2021, the total diagnosed prevalent cases of PF-ILD in the US were 166,393 cases which is expected to rise by 2032.
Key benefits of the Indication Market report:
- The report covers a descriptive overview of Progressive fibrosing interstitial lung diseases, explaining its signs and symptoms, causes, classification, and currently available therapies.
- Comprehensive insight has been provided into the Progressive Fibrosing Interstitial Lung Disease epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Fibrosing Interstitial Lung Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Progressive Fibrosing Interstitial Lung Disease market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Progressive Fibrosing Interstitial Lung Disease market.
Got queries? Click here to learn more about Progressive Fibrosing Interstitial Lung Disease Insights
Progressive fibrosing interstitial lung diseases Overview
Progressive fibrosing interstitial lung diseases (PF-ILD) consist of a diverse group of interstitial lung diseases (ILD) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Treatment for ILDs varies depending on the type of ILD diagnosed and the severity. Lung damage from ILDs is often irreversible and progressive, so treatment normally centers on relieving symptoms, improving quality of life, and slowing the disease’s progression. Medications, such as corticosteroids, can be used to decrease inflammation in the lungs.
Nintedanib (Ofev) is the only approved drug in the PF-ILD treatment landscape. Along with Ofev the current market is mainly attributed to corticosteroids and immunosuppressants for treatment. Novel uses of antifibrotic therapies are emerging due to a paucity of evidence-based treatments for multiple ILD subtypes. The market is anticipated to expect launch of several emerging therapies in PF- ILD treatment domain in the forecast period.
Progressive fibrosing interstitial lung diseases Epidemiological Insights:
- In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Interstitial Lung disease (ILD) in the 7MM were 894,597 in 2021. Out of these, around 322,197 cases were estimated to be of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM.
- The United States showed the highest diagnosed prevalent cases of ILD compared to the other 7MM countries. In 2021, the total number of diagnosed prevalent cases of ILD in the US were 487,213 which is anticipated to increase by 2032. This formed around 54% of the total diagnosed prevalent cases of ILD in the 7MM.
- In the EU5, total diagnosed prevalent cases of ILD in 2021 were 334,050 which is expected to increase considerably in the forecast time period (2022-2032). Additionally, among the 7MM regions (US, EU5, Japan), Japan has the lowest share of diagnosed patient pool of Interstitial Lung Disease.
Progressive fibrosing interstitial lung diseases Epidemiological Segmentation
- Total Progressive fibrosing interstitial lung diseases, prevelant cases
- Total Progressive fibrosing interstitial lung diseases, prevelant diagnosed cases
- Total Progressive fibrosing interstitial lung diseases, type-specific diagnosed Prevalent cases
Progressive Fibrosing Interstitial Lung Disease Outlook
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
ILD and its progressing forms form a substantial proportion of disabling chronic lung diseases leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes which are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuate the launch of emerging therapies.
In the upcoming treatment landscape, there are a plethora of companies investigating agents for use in the PF-ILD and IPF-specific PF-ILD which includes Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd., Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB. There are many more pharma companies that are conducting clinical trials for therapies of PF-ILD and IPF-specific PF-ILD.
Learn more by requesting for sample @ Progressive Fibrosing Interstitial Lung Disease Landscape
Progressive fibrosing interstitial lung diseases Key Companies
- Boehringer Ingelheim
- FibroGen
- Bristol-Myers Squibb
- And many others
Progressive fibrosing interstitial lung diseases Therapies
- BI 1015550
- Pamrevlumab
- BMS-986278
- And many others
Market Drivers
- Advancement in research and development
- Exponential Market Growth
Market Barriers
- Dry clinical pipeline for Non-IPF PFI-ILDz
- Diagnostic Barrier
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Progressive fibrosing interstitial lung diseases,
- Disease Background and Overview
- Epidemiology and patient population
- Progressive fibrosing interstitial lung diseases, Emerging Therapies
- Progressive fibrosing interstitial lung diseases, Market Outlook
- Market Access and Reimbursement of Therapies
- Market Drivers
- Market Barriers
- Appendix
- Progressive fibrosing interstitial lung diseases, Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Progressive fibrosing interstitial lung diseases Market Insights
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com